Introduction/Background Brain metastases (BMs) from ovarian cancer (OC) are extremely rare and have a very poor prognosis. Studies on brain metastatic OC are limited by low number of participants.

Methodology We aimed to analyze patients with brain metastases from ovarian cancer (OC), fallopian tube carcinoma (FTC) and primary peritoneal carcinoma (PPC) in a single center experience.

Methods: All women with OC, FTC and PPC with BMs, who were treated in Oncogynecological Department of N.N. Alexandrov National Cancer Centre of Belarus between January 1980 and December 2022 were retrospectively identified. The main criteria were serous carcinoma, endometrioid carcinoma and clear cell carcinoma and brain metastases.

Results At the initial analysis, 125 patients were selected, but during the final and detailed processing, 106 patients with BMs met the inclusion criteria (the final histological diagnosis of 20 patients did not meet the inclusion criteria). A total of 106 patients were analyzed: all patients with OC. The mean was 61.42 ± 9.94 (95% CI [59.52; 63.32]) years. In most cases, the patients were urban residents (83%). Most often, stage III of the disease was established (58%), serous carcinoma prevailed (97%). Specific anticancer treatment was not provided at 12%.

A multimodal approach (surgery combined with radiotherapy and chemotherapy) used in 21% of patients with BMs. Surgical treatment or radiotherapy or chemotherapy were used only in 24% of patients, chemoradiotherapy was used in 34%. 18% of patients survived

Conclusion BMs from OC remain a rare event, and the overall quality of current evidence is limited, and more studies with homogeneous groups are needed to determine the best treatment actions.

Disclosures The authors have nothing to disclose.